Johnson & Johnson is planning manufacturing, R&D and technology investments of more than $55 billion in the US over the next four years.
The healthcare giant said this represents a 25% increase in investment compared to the previous four years.
The investments start with breaking ground on a new medicine manufacturing facility in North Carolina, and will be followed with three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses, although it did not reveal where those sites will be.
Johnson & Johnson also said it plans to make “significant investments in extensive R&D infrastructure” aimed at developing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery. It also said it would increase technology investments to help make drug discovery and development faster.
The company said the new 500,000-square-foot biologics manufacturing facility in Wilson, North Carolina will expand its capacity to manufacture medicines for people living with cancer, immune-mediated and neurological diseases. It will support approximately 5,000 jobs during construction and, once operational, will employ over 500 employees and contractors, including process technicians, laboratory analysts, engineers and microbiologists.
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, chairman and chief executive of Johnson & Johnson.
In February Eli Lilly also announced plans to boost its medicine production by building four new pharmaceutical manufacturing sites in the US.
Three of the planned US sites will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies.
Across these four new sites, Lilly expects to create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians, and create nearly 10,000 construction jobs during the development of the sites.
"To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations.
More news on life sciences and innovation
- SCI research: UK life sciences missing out on billions through competitiveness gap
- Life sciences and clean energy core to new Industrial Strategy
- Pharma R&D: Who is really setting the pace?
- Europe's chemical sector 'is at breaking point' warns report
- R&D: Here's how pharma and chemicals industries are performing
Visit Blog